Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

                   
yahoo.com     May 21, 2008            

Wednesday May 21, 9:00 am ET - Innovative pipeline products highlight Watson's commitment to urology - The abstracts include a cardiac safety trial involving silodosin, an investigational treatment for benign prostatic hyperplasia (BPH, or prostate enlargement) and a pharmacokinetic study of... [read full story]                

Full Coverage
                   

Watson Announces Positive Data For Its New Investigational Products For Benign Prostatic...

medicalnewstoday.com     May 22, 2008          

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that investigators presented clinical data on two Phase 3 products at the American Urological Association's annual meeting. The abstract (Steady-State Pharmacokinetics of an Investigational...                

comments

                   

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic...

drugs.com     May 22, 2008          

- Innovative pipeline products highlight Watson's commitment to urology - ORLANDO, Fla., May 21, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that investigators presented...                

comments

Watson Reports Positive Phase III Data for Prostate and Bladder Drugs

redorbit.com     May 22, 2008          

Watson Pharmaceuticals has announced positive data from clinical studies on two Phase III products - silodosin, an investigational treatment for benign prostatic hyperplasia and oxybutynin chloride topical gel, an investigational product for overactive bladder.                

comments